Leandro Bueno Bergantin
Overview
Explore the profile of Leandro Bueno Bergantin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
83
Followers
0
Related Specialties
Related Specialties
Co-Authors
Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bergantin L
Psychiatry Res
. 2020 Jun;
291:113167.
PMID: 32562933
A link between depression and obesity has been established by several reports. Consistent data support a bidirectional link between depression and obesity, e.g. obese people have demonstrated an increased risk...
12.
Bergantin L
Curr Drug Res Rev
. 2020 Feb;
12(2):97-102.
PMID: 32065096
Background: The interactions between Alzheimer's Disease (AD) and major depression can be translated into clinical data showing that depressive patients have had an enhanced risk for developing AD (later in...
13.
Bergantin L
Curr Protein Pept Sci
. 2020 Feb;
21(12):1223-1228.
PMID: 32026774
Background: Parkinson´s disease (PD) and depression have an interplay at multiple cellular levels, a phenomenon which is translated into clinical data showing that depressive patients presented an enhanced risk for...
14.
Bergantin L
Cancer Lett
. 2019 Feb;
448:128-131.
PMID: 30771427
The incidence of both cancer and diabetes is dramatically increasing in worldwide population, costing many millions from governments into expenditures related to medical health systems. Diabetes has been clinically linked...
15.
Bergantin L
Pharmacol Res
. 2019 Jan;
141:298-302.
PMID: 30639385
Many reports have been demonstrating off-label effects for calcium (Ca) channel blockers (CCBs), for example: patients medicated with CCBs have had an improvement of their diabetes status (control of glycemia),...
16.
Bergantin L
Curr Hypertens Rev
. 2018 Aug;
15(1):32-39.
PMID: 30117399
Background: Hypertension, diabetes and neurodegenerative diseases are among the most prevalent medical problems around the world, costing millions of dollars to the medical health systems. Indeed, hypertension has been associated...
17.
Bergantin L, Caricati-Neto A
Eur J Pharmacol
. 2016 Jun;
788:255-260.
PMID: 27349146
In 2013, we discovered that the entitled "calcium paradox" phenomenon, which means a paradoxical sympathetic hyperactivity produced by l-type Ca(2+) channel blockers (CCBs), used in antihypertensive therapy, is due to...
18.
Caricati-Neto A, Garcia A, Bergantin L
Pharmacol Res Perspect
. 2015 Oct;
3(5):e00181.
PMID: 26516591
In this review, we discussed pharmacological implications of the Ca(2+)/cAMP signaling interaction in the antihypertensive and neurological/psychiatric disorders therapies. Since 1975, several clinical studies have reported that acute and chronic...
19.
Bergantin L, Souza C, Ferreira R, Smaili S, Jurkiewicz N, Caricati-Neto A, et al.
Cell Calcium
. 2013 Jul;
54(3):202-12.
PMID: 23849429
It is well established that reduction of Ca2+ influx through L-type voltage-dependent Ca2+ channel (L-type VDCC), or increase of cytosolic cAMP concentration ([cAMP]c), inhibit contractile activity of smooth muscles in...
20.
Bergantin L, Figueiredo L, Godinho R
J Appl Physiol (1985)
. 2011 Sep;
111(6):1710-8.
PMID: 21921242
The molecular regulation of skeletal muscle proteolysis and the pharmacological screening of anticatabolic drugs have been addressed by measuring tyrosine release from prepubertal rat skeletal muscles, which are thin enough...